{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:33:19Z","timestamp":1785569599887,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03034-1","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T07:24:30Z","timestamp":1731137070000},"page":"233-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)"],"prefix":"10.1007","volume":"42","author":[{"given":"Saakshi","family":"Khattri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Gonz\u00e1lez-Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Engin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Martimianaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Alsharafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Konicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"11","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.36849\/JDD.6040","volume":"20","author":"R Dave","year":"2021","unstructured":"Dave R, Alkeswani A. An overview of biologics for psoriasis. J Drugs Dermatol. 2021;20(11):1246\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"17","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"H-J Lee","year":"2023","unstructured":"Lee H-J, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24(17):13313.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35\u201355.","journal-title":"BioDrugs"},{"issue":"19","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"3","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"adv00032","DOI":"10.2340\/00015555-3386","volume":"100","author":"C Reid","year":"2020","unstructured":"Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032.","journal-title":"Acta Derm Venereol"},{"key":"3034_CR7","doi-asserted-by":"crossref","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic treatments of psoriasis: an update for the clinician. Biol Targets Ther. 2021:39\u201351.","DOI":"10.2147\/BTT.S252578"},{"key":"3034_CR8","unstructured":"AAD. Psoriasis Clinical Guideline. 2023. https:\/\/www.aad.org\/member\/clinical-quality\/guidelines\/psoriasis."},{"key":"3034_CR9","unstructured":"NHS. Psoriasis Biologic Drug Treatment Pathway. 2020. https:\/\/selondonccg.nhs.uk\/wp-content\/uploads\/dlm_uploads\/2021\/09\/Psoriasis-Biologic-Pathway-ADULTS-July-2020-FINAL.pdf."},{"issue":"1","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","volume":"20","author":"L Rusi\u00f1ol","year":"2024","unstructured":"Rusi\u00f1ol L, Carmona-Rocha E, Puig L. Durability and long-term outcomes of biologic therapies in psoriasis. Expert Rev Clin Immunol. 2024;20(1):71\u201382.","journal-title":"Expert Rev Clin Immunol"},{"key":"3034_CR11","doi-asserted-by":"publisher","first-page":"adv40556","DOI":"10.2340\/actadv.v104.40556","volume":"104","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, et al. Identifying predictors of PASI100 responses up to month 12 in patients with moderate-to-severe psoriasis receiving biologics in the psoriasis study of health outcomes (PSoHO). Acta dermato-venereol. 2024;104:adv40556.","journal-title":"Acta dermato-venereol"},{"key":"3034_CR12","doi-asserted-by":"crossref","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, Reich A, Zaheri S, Costanzo A, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022.","DOI":"10.1111\/jdv.18376"},{"key":"3034_CR13","doi-asserted-by":"crossref","unstructured":"Pinter A, Costanzo A, Khattri S, Smith S, Carrascosa J, Tada Y, et al. Comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the international, observational psoriasis study of health outcomes (PSoHO). Dermatol Ther. 2023:1\u201315.","DOI":"10.1007\/s13555-023-01086-9"},{"issue":"3","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","volume":"40","author":"C Lynde","year":"2023","unstructured":"Lynde C, Riedl E, Maul J-T, Torres T, Pinter A, Fabbrocini G, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869\u201386.","journal-title":"Adv Ther"},{"key":"3034_CR15","doi-asserted-by":"crossref","unstructured":"Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, et al. Baseline characteristics and mNAPSI change from baseline scores through month 12 for patients with moderate-to-severe plaque psoriasis and concomitant nail psoriasis treated with biologics from PSoHO. Dermatol Ther. 2024:1\u20139.","DOI":"10.1007\/s13555-024-01150-y"},{"key":"3034_CR16","unstructured":"FDA Approves BIMZELX\u00ae. https:\/\/www.psoriasis.org\/advance\/fda-approves-bimzelx\/#:~:text=National%20Psoriasis%20Foundation-,FDA%20Approves%20BIMZELX%C2%AE,moderate%20to%20severe%20plaque%20psoriasis.&text=%E2%80%9CBimekizumab%20(BIMZELX%C2%AE)%20is,the%20FDA%20to%20treat%20psoriasis."},{"key":"3034_CR17","unstructured":"EMA. Bimzelx. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx."},{"key":"3034_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13555-019-00337-y","volume":"10","author":"RB Warren","year":"2020","unstructured":"Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses. Dermatol Ther. 2020;10:73\u201386.","journal-title":"Dermatol Ther"},{"key":"3034_CR19","unstructured":"Leonardi C, Langley R, Blauvelt A, Gordon K, Shrom D, Kerr L, et al., editors. Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: a pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3). Journal of the American Academy of Dermatology. New York: MOSBY-ELSEVIER; 2016."},{"issue":"9","key":"3034_CR20","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/jdv.19161","volume":"37","author":"A Reich","year":"2023","unstructured":"Reich A, Pinter A, Maul J, Vender R, Torres T, Brnabic A, et al. Speed of clinical improvement in the real-world setting from patient-reported psoriasis symptoms and signs diary: secondary outcomes from the psoriasis study of health outcomes through 12 weeks. J Eur Acad Dermatol Venereol JEADV. 2023;37(9):1825\u201340.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"3034_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","volume":"99","author":"Y Tada","year":"2020","unstructured":"Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci. 2020;99(1):53\u201361.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"3034_CR22","first-page":"CD011535","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"key":"3034_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","volume":"11","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2021;11:885\u2013905.","journal-title":"Dermatol Ther"},{"key":"3034_CR24","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res"},{"issue":"4","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/09546634.2021.1961998","volume":"33","author":"P Dapavo","year":"2022","unstructured":"Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatol Treat. 2022;33(4):2352\u20137.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"3034_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103465","volume":"28","author":"Y Tomar","year":"2023","unstructured":"Tomar Y, Gorantla S, Singhvi G. Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches. Drug Discov Today. 2023;28(2): 103465.","journal-title":"Drug Discov Today"},{"key":"3034_CR27","unstructured":"Augustin M, Gooderham M, Amato D, Gallo G, See K, McKean-Matthews M, Burge R, editors. Rapid clinical response predicts consistent long-term response in patients with moderate-to-severe psoriasis: Ixekizumab vs. ustekinumab. Journal of the American Academy of Dermatology. New York: Mosby-Elsevier; 2019."},{"issue":"2","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2475530321999087","volume":"6","author":"MC Johnson","year":"2021","unstructured":"Johnson MC, Heron CE, Ghamrawi RI, Balogh EA, Feldman SR. Speed of psoriasis treatment response for biologic agents: a review of phase III clinical trials. J Psoriasis Psoriatic Arthritis. 2021;6(2):99\u2013105.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"issue":"6","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358.","journal-title":"Br J Dermatol"},{"key":"3034_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567\u201379.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3034_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","volume":"33","author":"N Yasmeen","year":"2022","unstructured":"Yasmeen N, Sawyer LM, Malottki K, Levin L-\u00c5, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatol Treat. 2022;33(1):204\u201318.","journal-title":"J Dermatol Treat"},{"issue":"8","key":"3034_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, Augustin M, Neupane B, Kazmierska P, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. 2022;12(8):1777\u201392.","journal-title":"Dermatol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03034-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:35Z","timestamp":1738235015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03034-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03034-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Saakshi Khattri is a speaker for AbbVie, Janssen, Lilly, and UCB; serves as an advisory board member\/consultant for AbbVie, Janssen, Lilly, Novartis, and UCB; and has received research grants from AbbVie, BMS, LEO, Novartis, and Pfizer; \u00c1lvaro Gonz\u00e1lez-Cantero has served as a consultant for and received speaker fees from AbbVie, Janssen, Novartis, Almirall, Celgene, UCB, L'Oreal, MSD and Leo Pharma; Burhan Engin and Sunil Dogra has no conflict of interest to declare; Caroline A. Murphy, Christopher Schuster, Naoto Tsujimoto, Georgia Martimianaki, Anastasia Lampropoulou, Aya Alsharafi and Bruce Konicek are employees and shareholders of Eli Lilly and Company; Felix Lauffer has received speaker or consultant fees from Abbvie, Novartis Pharma, LEO Pharma, Lilly, Roche, Sanofi, Almirall, Janssen-Cilag Pharma Amgen, UCB Pharma, Boehringer-Ingelheim, Bristol-Myers-Squibb, and Union Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol, amendments, and consent documentation were approved by local institutional review boards (IRBs). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and\/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}